Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?

Journal of Clinical Pathology

Volumn 66, Issue 10, 2013, Pages 839-846

  Ou, Sai Hong Ignatius ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CRIZOTINIB; DABRAFENIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN RET; ROS1 PROTEIN; SCATTER FACTOR RECEPTOR; SELUMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

CANCER CHEMOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; EXON; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR DIAGNOSTICS; MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SKIN CARCINOMA; SMOKING;

LUNG CANCER; MOLECULAR PATHOLOGY; SMOKING;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84884959620     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201296     Document Type: Review

References (95)

1. Toh CK, Gao F, Lim WT, et al. Never-Smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-51. (Pubitemid 46630653)
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-90. (Pubitemid 47463669)
3. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007.;25:561-70. (Pubitemid 350002964)
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. (Pubitemid 47206930)
6. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203. (Pubitemid 350235027)
7. Ou SHI, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17:1351-75.
8. Chin LP, Soo RA, Soong R, et al. Targeting ROS1 with anaplastic lymphoma kinase inhibitors. A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 2012;17:1351-75.
9. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
10. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-51.
11. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;30;431:525-6.
12. Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013.;31:1039-49.
13. Ou SHI, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-93.
14. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
15. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-34.
16. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-19.
17. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-8.
18. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
19. Janne PA, Wang X, Socinski MA, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012.;30:2063-9.
20. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
21. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
22. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
23. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
24. Yang JCH, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012;30(suppl; abstr LBA7500).
25. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012;13:539-48.
26. Pham D, Kris MG, Reily G, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006;24:1700-4. (Pubitemid 46622141)
27. Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008;14:4877-82.
28. Sasaki H, Endo K, Takada M, et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007;58:324-8. (Pubitemid 350051507)
29. Lung-Iversen M, Kleinberg L, Fjellbirkeland L, et al. Clinicopathologic characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol 2012.;7:1471-3.
30. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013;8:179-84.
31. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-9.
32. Hata A, Katakami N, Yoshioka H, et al. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol 2013;8:89-95.
33. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
34. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-6. (Pubitemid 40478587)
35. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006;119:2586-91. (Pubitemid 44691311)
36. Sonobe M, Manabe T, Wada H, et al. Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. J Mol Diagn 2006;8:351-6. (Pubitemid 44063812)
37. Tomizawa K, Suda K, Onzato R, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011;74:139-44.
38. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011.;22:2616-24.
39. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7.
40. Cardarella S, Ortiz TM, Joshi VA, et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 2012.;7:1767-74.
41. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18:4910-18.
42. Mazieres J, Peters S, Cortot A, et al. Lung cancer harboring HER2 mutation: epidemiological characteristics and therapeutic perspectives. Ann Oncol 2012;23: supplement 9 ix403 (abstract number 1232).
43. De Grèvea J, Teugelsa E, Geersa C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123-7.
44. Janne PA, Kris M, Goldberg Z, et al. Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers. Presented at: European Society of Medical Oncology 2012 Congress; September 28-October 2, 2012; Vienna, Austria. Abstract 1228.
45. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010;29:49-60.
46. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008.;14:5731-4.
47. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010;69:272-8.
48. An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS ONE 2012;7:e40109.
49. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012;18:6169-77.
50. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutated advanced non-small-cell lung cancer: a randomized, multicenter, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47.
51. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112-21.
52. Martin P, Leighl NB, Tsao MS, et al. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 2013; epublished ahead of print.
53. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
54. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011.;29:3574-9.
55. Kobayashi M, Sonobe M, Takahashi T, et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res 2011.;31:4619-24.
56. Yousem SA, Nikiforova M, Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008;32:1317-21.
57. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013;24:742-8.
58. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;10: e23-4.
59. Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF Inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol 2013; epublished ahead of print.
60. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
61. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-23.
62. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009.;27:4247-53.
63. Yoshida A, Tsuta K, Watanabe SI, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011;72:309-15.
64. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
65. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;10:1011-19.
66. Kim DW, Ahn MJ, Shi Y, et al. Results of a global phase II study with crizotinib in ALK-positive NSCLC. J Clin Oncol 2012;30(suppl; abstr 7533).
67. Shaw AT, Kim DY, Nagakawa K, et al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007.). Ann Oncol 2012;23(Suppl 9):LBA1.
68. NCCN Clinical Practice Guidelines in Oncology Non-small Cell Lung Cancer version 2. 2013. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf (accessed 31 Mar 2013).
69. Ou SH, Jam J, Yen Y, et al. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther 2012;2:447-56.
70. Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 2011;6:e28204.
71. Bergethon K, Shaw AT, Ou SHI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
72. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-Positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res 2012;18:4449-57.
73. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-9.
74. Suehara Y, Arcila M, Wang L, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012;18:6599-608.
75. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Geonome Res 2012;22:2109-19.
76. Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer. A clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013.;37:554-62.
77. Kim HR, Lim SM, Kim HJ, et al. The frequency and impact on clinical outcomes of ROS1 rearrangement in never smokers with lung adenocarcinoma. Submitted.
78. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012;30 (suppl; abstract 7508).
79. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010;16:5936-41.
80. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
81. Li F, Feng Y, Fang R, et al. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 2012;22:928-31.
82. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012.;30:4352-9.
83. Cai W, Su C, Fan L, et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer 2013; [epublish ahead of print].
84. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013; [Epub ahead of print].
85. De Falco V, Buonocore P, Muthu M, et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab 2013; [Epub ahead of print].
86. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
87. Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012;7:1775-80.
88. Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification Is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2012;31:731-7.
89. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6:e20351.
90. Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012;18:6658-67.
91. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
92. Go H, Jeon YK, Park HL, et al. High MET gene copy number leads to shorter survival inpatients with non-small cell lung cancer. J Thorac Oncol 2010;5:305-13.
93. Ou SHI, Kwak E, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-6.
94. MET and EGFR mutations is identified in ALK-rearranged pulmonary adenocarcinoma. Molecular analysis of 25 ALK-positive cases. J Thorac Oncol 2013, [epublish ahead of print].
95. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29, (suppl; abstract 7506.).